Physician profile
Dawn E Downing
NPI 1154731941
$3,019.53
in general payments reported to CMS, 2019-2025
25 companies · $691 in 2025
The $691 reported for 2025 was more than what 78% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $807 · 2022: $600 · 2023: $376 · 2024: $546 · 2025: $691.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,613.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $475.66 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $446.29 | 2021-2025 | Airsupra, Farxiga, Bevespi Aerosphere |
| Abbvie INC. | $303.10 | 2021-2025 | |
| Novo Nordisk INC | $282.51 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Exact Sciences Corporation | $222.39 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $210.10 | 2021-2024 | |
| Glaxosmithkline, LLC. | $201.23 | 2021-2022 | |
| Amgen INC. | $157.39 | 2022-2025 | Otezla, Repatha, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.27 | 2021-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $70.87 | 2021-2024 | |
| Radius Health, INC. | $59.14 | 2021-2023 | Tymlos |
| Janssen Pharmaceuticals, INC | $57.58 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.73 | 2021-2023 | Jardiance, Synjardy |
| Dexcom, INC. | $55.58 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $53.77 | 2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $44.48 | 2021 | |
| Paratek Pharmaceuticals, INC. | $42.04 | 2021-2025 | Nuzyra |
| Abbott Laboratories | $33.77 | 2022-2025 | Freestyle Libre 3 |
| Hologic Sales and Service, LLC | $27.72 | 2024 | Aptima, Thinprep 2000 Processor |
| Phathom Pharmaceuticals, INC. | $22.81 | 2024 | Voquezna |
| Ultragenyx Pharmaceutical INC. | $22.74 | 2021 | |
| Insulet Corporation | $21.46 | 2025 | Omnipod |
| Astellas Pharma US INC | $20.43 | 2025 | Veozah |
| Sanofi-Aventis U.S. LLC | $15.69 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.78 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Downing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.